Cruz, Álvaro A.
Barile, Sara
Nudo, Elena
Brogelli, Laura
Guller, Patricia
Papi, Alberto
Funding for this research was provided by:
Chiesi Farmaceutici
Article History
Received: 2 November 2020
Accepted: 12 January 2021
First Online: 29 January 2021
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: AAC reports grants, personal fees or non-financial support from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi, Sanofi, Novartis, Mylan, Eurofarma and Mantecorp. AP reports grants, personal fees, non-financial support from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici TEVA and Sanofi/Regeneron; personal fees, non-financial support from Mundipharma, Zambon, Novartis; grants, personal fees and non-financial support from Menarini; personal fees from Roche, grants from Fondazione Maugeri, grants from Fondazione Chiesi, personal fees from Edmondpharma. SB, PG and EN are employed in Chiesi Farmaceutici SpA, Italy. LB has no conflict of interest to declare.